Phathom Pharmaceuticals (PHAT) Projected to Release Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is expected to be announcing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Phathom Pharmaceuticals to announce earnings of ($0.06) per share and revenue of $73.4450 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:00 AM ET.

Phathom Pharmaceuticals Stock Up 4.0%

Shares of Phathom Pharmaceuticals stock opened at $11.70 on Thursday. The business has a 50 day moving average of $10.90 and a 200 day moving average of $11.93. Phathom Pharmaceuticals has a 52 week low of $7.84 and a 52 week high of $18.31. The company has a market cap of $933.19 million, a PE ratio of -5.52 and a beta of 0.49.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PHAT. HC Wainwright reissued a “buy” rating and issued a $26.00 target price on shares of Phathom Pharmaceuticals in a research report on Wednesday, June 17th. Barclays upgraded Phathom Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $16.00 to $18.00 in a research report on Friday, March 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $24.50.

Hedge Funds Weigh In On Phathom Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Millennium Management LLC grew its position in Phathom Pharmaceuticals by 125.8% during the 3rd quarter. Millennium Management LLC now owns 5,081,451 shares of the company’s stock valued at $59,809,000 after purchasing an additional 2,830,954 shares during the last quarter. Moore Capital Management LP bought a new stake in Phathom Pharmaceuticals during the 2nd quarter valued at about $5,754,000. Invesco Ltd. lifted its stake in shares of Phathom Pharmaceuticals by 13.4% in the second quarter. Invesco Ltd. now owns 4,140,072 shares of the company’s stock worth $39,703,000 after buying an additional 489,260 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Phathom Pharmaceuticals by 15.4% in the third quarter. Vanguard Group Inc. now owns 3,215,572 shares of the company’s stock worth $37,847,000 after buying an additional 428,261 shares in the last quarter. Finally, SummitTX Capital L.P. purchased a new stake in shares of Phathom Pharmaceuticals during the third quarter valued at approximately $4,543,000. Hedge funds and other institutional investors own 99.01% of the company’s stock.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical?stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium?competitive acid blocker (P-CAB) licensed for use in the United States.